{
  "abstract": "Background: Venetoclax plus azacitidine (Ven-Aza) marked a milestone in the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy, following the VIALE-A trial, which demonstrated a significant survival benefit. In 2024, a pilot project was implemented to expand access to Ven-Aza within the Brazilian Public Health System (SUS). Real-world data from this population may help evaluate treatment effectiveness and support policies for equitable access to novel technologies. Aim: To present a preliminary analysis of the epidemiological and clinical profile and outcomes of SUS patients with AML, ineligible for intensive chemotherapy, treated with venetoclax and azacitidine. Materials and methods: Retrospective study based on review of electronic medical records of AML patients followed between May 2024 and August 2026. Data collected included age, sex, AML classification (primary/secondary), prior azacitidine monotherapy, number of cycles, treatment duration, survival, and mortality. Overall survival (OS) was estimated using the Kaplan-Meier method, from treatment initiation to last assessment or death. Statistical analysis was performed in SPSS v25. Results: Fifteen patients were included, with a median age of 62 years (range, 48–84) and 73% female. Secondary AML was present in 53% of cases, and 47% had received prior azacitidine monotherapy. Median number of cycles was 2. Febrile neutropenia occurred in 80% of patients. Median OS was 6.8 months (95% CI, 1.3–18.2). Overall mortality was 60%, with early mortality of 6.7% (D30) and 29.5% (D60). Discussion: This analysis represents an initial real-world case series of AML patients treated with Ven-Aza within the SUS. Compared with the VIALE-A pivotal trial, 30-day mortality was similar (∼7%), but OS was markedly shorter (6.8 vs. 14.7 months). A UK NHS real-world cohort reported longer OS (13.6 months) and lower D30/D60 mortality (5%/8%), suggesting that population- and access-related differences may contribute to the outcomes observed. Febrile neutropenia was also more frequent than reported in VIALE-A (∼42%). Expanding this cohort and comparing findings with supplementary (private) health data may clarify these differences. Real-world evidence from SUS patients, particularly in the Northeast, is essential to evaluate treatment effectiveness under routine care, inform cost-effectiveness analyses, and support equitable AML treatment access in the public health system.",
  "abstract_shown": true,
  "affiliations": [
    "Hospital Santa Izabel, Oncoclínicas, Salvador Bahia, Salvador, BA, Brazil"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Beatriz Moura PORTUGAL"
    },
    {
      "affs": [
        0
      ],
      "name": "Valney Oliveira Santos JUNIOR"
    },
    {
      "affs": [
        0
      ],
      "name": "Maura Alice Santos ROMEO"
    },
    {
      "affs": [
        0
      ],
      "name": "Luiz Henrique dos Santos de ASSIS"
    },
    {
      "affs": [
        0
      ],
      "name": "Giulia Beatriz Correia MATOS"
    },
    {
      "affs": [
        0
      ],
      "name": "Lorhane Nunes dos ANJOS"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c8dbq49j0crg7.bib",
  "cited_by": 0,
  "doi": "10.1016/j.htct.2026.107584",
  "fulltext_url": "http://www.sciencedirect.com/science/article/pii/S2531137926013313",
  "id": "c8dbq49j0crg7",
  "issns": [
    "2531-1379",
    "2531-1387"
  ],
  "landing_url": "https://doi.org/10.1016/j.htct.2026.107584",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC633-647.5"
    ],
    [
      "openalex",
      "2720|Acute Myeloid Leukemia Research"
    ]
  ],
  "openalex": "W7223116075",
  "pdf_url": "https://www.sciencedirect.com/science/article/pii/S2531137926013313/pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-23",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/c8dbq49j0crg7.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:43:29Z",
      "native_id": "fc078b3af15c40af93e827ed0c4cb68a",
      "source": "doaj",
      "url": "https://doi.org/10.1016/j.htct.2026.107584"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC633-647.5",
      "subfield": "endocrinology-metabolism"
    }
  ],
  "title": "EPIDEMIOLOGICAL PROFILE AND OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS): PRELIMINARY ANALYSIS OF A REAL-WORLD PILOT PROJECT",
  "title_text": "EPIDEMIOLOGICAL PROFILE AND OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS): PRELIMINARY ANALYSIS OF A REAL-WORLD PILOT PROJECT",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:43:29Z",
  "url": "https://research.draconitic.com/paper/c8dbq49j0crg7",
  "venue": "Hematology, Transfusion and Cell Therapy",
  "versions": []
}